Sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma: A prospective, open-label, single-arm, phase II clinical study

ObjectiveTo evaluate the efficacy and safety of sintilimab combined with apatinib plus capecitabine in the treatment of unresectable hepatocellular carcinoma (HCC) to provide a more effective first-line treatment for patients with advanced HCC.MethodsThis open-label, prospective, phase II study incl...

Бүрэн тодорхойлолт

Номзүйн дэлгэрэнгүй

Үндсэн зохиолчид:	Dailong Li, Lu Xu, Jinxing Ji, Dan Bao, Juan Hu, Ying Qian, Yinjie Zhou, Zhuo Chen, Daojun Li, Xiaopeng Li, Xiaoling Zhang, Hao Wang, Changjun Yi, Menglu Shi, Yaqi Pang, Siqi Liu, Xinhua Xu
Формат:	Artigo
Хэл сонгох:	Inglês
Хэвлэсэн:	Frontiers Media S.A. 2022-08-01
Цуврал:	Frontiers in Immunology
Нөхцлүүд:	apatinib capecitabine first-line treatment hepatocellular carcinoma immune checkpoint inhibitors sintilimab
Онлайн хандалт:	https://www.frontiersin.org/articles/10.3389/fimmu.2022.944062/full
Шошгууд:	Шошго нэмэх Шошго байхгүй, Энэхүү баримтыг шошголох эхний хүн болох!